These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 27881132)

  • 21. Comparative Meta-Analysis of the Efficacy of Once-Daily Fluticasone Furoate 100 µG Versus Twice-Daily Fluticasone Propionate 250 µG in Adolescents and Adults with Persistent Asthma.
    Tomlinson R; Parks D; Martin A
    Lung; 2017 Oct; 195(5):571-574. PubMed ID: 28755137
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Fluticasone propionate powder: oral corticosteroid-sparing effect and improved lung function and quality of life in patients with severe chronic asthma.
    Nelson HS; Busse WW; deBoisblanc BP; Berger WE; Noonan MJ; Webb DR; Wolford JP; Mahajan PS; Hamedani AG; Shah T; Harding SM
    J Allergy Clin Immunol; 1999 Feb; 103(2 Pt 1):267-75. PubMed ID: 9949318
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Efficacy and safety evaluation of once-daily fluticasone furoate/vilanterol in Asian patients with asthma uncontrolled on a low- to mid-strength inhaled corticosteroid or low-dose inhaled corticosteroid/long-acting beta2-agonist.
    Lin J; Tang H; Chen P; Wang H; Kim MK; Crawford J; Jacques L; Stone S
    Allergy Asthma Proc; 2016 Jul; 37(4):302-10. PubMed ID: 27401316
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Regular treatment with formoterol and an inhaled corticosteroid versus regular treatment with salmeterol and an inhaled corticosteroid for chronic asthma: serious adverse events.
    O'Shea O; Stovold E; Cates CJ
    Cochrane Database Syst Rev; 2021 Apr; 4(4):CD007694. PubMed ID: 33852162
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Once-daily fluticasone furoate alone or combined with vilanterol in persistent asthma.
    O'Byrne PM; Bleecker ER; Bateman ED; Busse WW; Woodcock A; Forth R; Toler WT; Jacques L; Lötvall J
    Eur Respir J; 2014 Mar; 43(3):773-82. PubMed ID: 24136330
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The efficacy of fluticasone furoate administered in the morning or evening is comparable in patients with persistent asthma.
    Kempsford RD; Bal J; Baines A; Renaux J; Ravindranath R; Thomas PS
    Respir Med; 2016 Mar; 112():18-24. PubMed ID: 26823210
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Once-daily mometasone plus indacaterol versus mometasone or twice-daily fluticasone plus salmeterol in patients with inadequately controlled asthma (PALLADIUM): a randomised, double-blind, triple-dummy, controlled phase 3 study.
    van Zyl-Smit RN; Krüll M; Gessner C; Gon Y; Noga O; Richard A; de Los Reyes A; Shu X; Pethe A; Tanase AM; D'Andrea P;
    Lancet Respir Med; 2020 Oct; 8(10):987-999. PubMed ID: 32653075
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The combination of fluticasone furoate and vilanterol trifenatate in the management of asthma: clinical trial evidence and experience.
    Albertson TE; Richards JR; Zeki AA
    Ther Adv Respir Dis; 2016 Feb; 10(1):43-56. PubMed ID: 26668137
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A randomised, phase III trial of once-daily fluticasone furoate/vilanterol 100/25 μg versus once-daily vilanterol 25 μg to evaluate the contribution on lung function of fluticasone furoate in the combination in patients with COPD.
    Siler TM; Nagai A; Scott-Wilson CA; Midwinter DA; Crim C
    Respir Med; 2017 Feb; 123():8-17. PubMed ID: 28137501
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Inhaled corticosteroids in children with persistent asthma: effects on growth.
    Zhang L; Prietsch SO; Ducharme FM
    Cochrane Database Syst Rev; 2014 Jul; 2014(7):CD009471. PubMed ID: 25030198
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Safety and tolerability of the novel inhaled corticosteroid fluticasone furoate in combination with the β2 agonist vilanterol administered once daily for 52 weeks in patients >=12 years old with asthma: a randomised trial.
    Busse WW; O'Byrne PM; Bleecker ER; Lötvall J; Woodcock A; Andersen L; Hicks W; Crawford J; Jacques L; Apoux L; Bateman ED
    Thorax; 2013 Jun; 68(6):513-20. PubMed ID: 23440247
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Efficacy and safety comparison: Fluticasone furoate and fluticasone propionate, after step down from fluticasone furoate/vilanterol in Japanese patients with well-controlled asthma, a randomized trial.
    Adachi M; Goldfrad C; Jacques L; Nishimura Y
    Respir Med; 2016 Nov; 120():78-86. PubMed ID: 27817819
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Efficacy and safety of once-daily fluticasone furoate/vilanterol (FF/VI) versus twice-daily inhaled corticosteroids/long-acting β
    Devillier P; Humbert M; Boye A; Zachgo W; Jacques L; Nunn C; West S; Nicholls A; Antoun Z; Spinu L; Grouin JM
    Respir Med; 2018 Aug; 141():111-120. PubMed ID: 30053956
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Fluticasone furoate/vilanterol: a review of its use in patients with asthma.
    Syed YY
    Drugs; 2015 Mar; 75(4):407-18. PubMed ID: 25648266
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Ciclesonide versus other inhaled corticosteroids for chronic asthma in children.
    Kramer S; Rottier BL; Scholten RJ; Boluyt N
    Cochrane Database Syst Rev; 2013 Feb; 2013(2):CD010352. PubMed ID: 23450613
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Long-term efficacy and safety of fluticasone propionate powder administered once or twice daily via inhaler to patients with moderate asthma.
    ZuWallack R; Adelglass J; Clifford DP; Duke SP; Wire PD; Faris M; Harding SM
    Chest; 2000 Aug; 118(2):303-12. PubMed ID: 10936117
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Once-daily, single-inhaler mometasone-indacaterol-glycopyrronium versus mometasone-indacaterol or twice-daily fluticasone-salmeterol in patients with inadequately controlled asthma (IRIDIUM): a randomised, double-blind, controlled phase 3 study.
    Kerstjens HAM; Maspero J; Chapman KR; van Zyl-Smit RN; Hosoe M; Tanase AM; Lavecchia C; Pethe A; Shu X; D'Andrea P;
    Lancet Respir Med; 2020 Oct; 8(10):1000-1012. PubMed ID: 32653074
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Inhaled fluticasone propionate delivered by means of two different multidose powder inhalers is effective and safe in a large pediatric population with persistent asthma.
    Peden DB; Berger WE; Noonan MJ; Thomas MR; Hendricks VL; Hamedani AG; Mahajan P; House KW
    J Allergy Clin Immunol; 1998 Jul; 102(1):32-8. PubMed ID: 9679845
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Potential effects of fluticasone propionate on bone mineral density in patients with asthma: a 2-year randomized, double-blind, placebo-controlled trial.
    Kemp JP; Osur S; Shrewsbury SB; Herje NE; Duke SP; Harding SM; Faulkner K; Crim CC
    Mayo Clin Proc; 2004 Apr; 79(4):458-66. PubMed ID: 15065610
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Efficacy and safety of fluticasone/formoterol combination therapy in patients with moderate-to-severe asthma.
    Corren J; Mansfield LE; Pertseva T; Blahzko V; Kaiser K
    Respir Med; 2013 Feb; 107(2):180-95. PubMed ID: 23273405
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.